相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F
Franz X. Schaub et al.
BLOOD (2009)
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
Tiziano Barbui et al.
BLOOD (2009)
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones
Philip A. Beer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy
Peter J. Campbell et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Damla Olcaydu et al.
NATURE GENETICS (2009)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
Sai Li et al.
BLOOD (2008)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2008)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
Philip A. Beer et al.
BLOOD (2008)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt et al.
BLOOD (2008)
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Isabelle Plo et al.
BLOOD (2008)
Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells
Sophie Laffont et al.
BLOOD (2008)
Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders
Rui Zhao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34(+) cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis
Sandra G. Olthof et al.
STEM CELLS (2008)
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes
Bridget S. Wilkins et al.
BLOOD (2008)
Non-inferiority trials are unethical because they disregard patients' interests
Silvio Garattini et al.
LANCET (2007)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Mechanisms of disease: The myeloproliferative disorders
Peter J. Campbell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Linda M. Scott et al.
BLOOD (2006)
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Robert Kralovics et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders
Christine Bellanne-Chantelot et al.
BLOOD (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
AP Wolanskyj et al.
MAYO CLINIC PROCEEDINGS (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
